Khurram Rana

All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study

David R. Nelson, James N. Cooper, Jacob Lalezari et al. · Hepatology · 2015 · 689 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)

Keith S. Kaye, Andrew F. Shorr, Richard G. Wunderink et al. · The Lancet Infectious Diseases · 2023 · 286 citations

Pharmacy, Infectious Diseases, Pharmacology +14

The Innate Immune Response, Clinical Outcomes, and Ex Vivo HCV Antiviral Efficacy of a TLR7 Agonist (PF-4878691)

Mark Fidock, B E Souberbielle, Carl Laxton et al. · Clinical Pharmacology & Therapeutics · 2011 · 70 citations

Life Sciences, Infectious Diseases, Pharmacology +17

The Safety and Efficacy of Granulocyte‐Macrophage Colony‐Stimulating Factor (Sargramostim) Added to Indinavir‐ or Ritonavir‐Based Antiretroviral Therapy: A Randomized Double‐Blind, Placebo‐Controlled Trial

Gail Skowron, Daniel S. Stein, George L. Drusano et al. · The Journal of Infectious Diseases · 1999 · 30 citations

Medicine, Pharmacology, Pharmacotherapy +17

On‐treatment <scp>HCV RNA</scp> as a predictor of sustained virological response in <scp>HCV</scp> genotype 3–infected patients treated with daclatasvir and sofosbuvir

Kris V. Kowdley, David R. Nelson, Jacob Lalezari et al. · Liver International · 2016 · 25 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17